Evaluation of l toxicity and efficacy of anti-cytomegalovirus and anti- herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015

Journal of Infectious Diseases

Volumn 175, Issue 6, 1997, Pages 1308-1316

  Flores Aguilar, Marissa ^b   Besen, Gilberto ^b   Vuong, Chau ^b   Tatebayashi, Misako ^b   Munguia, David ^b   Gangan, Pacifico ^b   Wiley, Clayton A ^b   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; FOMIVIRSEN; ISIS 4015; NUCLEOTIDE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFECT; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS; SWINE; TOXICITY TESTING; ANIMAL; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; RETINA;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; HERPESVIRUS 1, HUMAN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; RETINA; RETINITIS; SWINE; THIONUCLEOTIDES;

EID: 0030612405     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516461     Document Type: Article

References (14)

1. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990;1049:99-125.
2. Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol 1993;7:11-2.
3. Berman ER. The vitreous. In: Biochemistry of the eye. New York: Plenum Press, 1991:304-5.
4. Jabs DA, Newman C, de Bustros S, Polk BF. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94:824-30.
5. Lehoang P, Girard B, Robinet M, et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989;96:865-74.
6. Cantrill HL, Henry K, Melroe H, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 1989;96:367-74.
7. Hodge WO, Lalonde RG, Sampalis J, Deschenes J. Once weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. J Infect Dis 1996;174:393-6.
8. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531-9.
9. Tatebayashi M, Neyts J, Besen G, et al. Absence of infectious retinitis after HCMV injection in rabbit eyes. J Infect Dis 1995;171:782-7.
10. Azad RF, Driver VB, Rosanne TK, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993;37:1945-54.
11. Vickers T, Baker BF, Cook PD, et al. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res 1991;19:3359-68.
12. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD 169. Curr Top Microbiol Immunol 1992;154:125-69.
13. Azad RF, Brown-Driver V, Buckheit RW, Anderson KP. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res 1995;28:101-11.
14. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996;40:2004-11.